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Abstract
Introduction. Acetylsalicylic acid (ASA) is the antiplatelet drug most used in the perioperative period in patients under-
going coronary artery bypass grafting (CABG). Off-pump coronary artery bypass grafting (OPCAB) is likely to alter platelet 
(PLT) function to a lesser extent than CABG with the use of cardiopulmonary bypass and may potentially result in high 
on-aspirin platelet reactivity (HAPR) in the postoperative period.
Materials and methods. The aim of this prospective study was to characterise serum thromboxane B2 (TXB2) variability 
and ASA-dependent platelet reactivity in patients with stable coronary artery disease undergoing OPCAB treated with 
a single daily dose of 75 mg of ASA. Blood sampling was performed 2 hours and 24 hours after ASA intake on the day 
before surgery, and on the 2nd and 7th days after the operation.
Results. A PLT counts reduction and a mean platelet volume increase were observed on the 2nd day after OPCAB. A PLT 
counts increase was found on the 7th postoperative day. A significant increase (p = 0.03) in the percentage of patients 
with insufficient laboratory ASA efficacy (defined by serum TXB2 ≥ 7.2 ng/mL) was observed on the 7
th postoperative day 
compared to preoperative values (52% vs 20% respectively, p = 0.02). A significant increase in median platelet reactivity 
and in the percentage of patients with HAPR (defined by VerifyNow® Aspirin test result ≥ 550 ARU) was observed on the 
7th postoperative day in comparison with the values before OPCAB (48% vs 12%, p = 0.007).
Conclusions. In the group of patients taking a standard daily dose of 75 mg of ASA, a substantial number of patients 
failed to attain optimal inhibition of serum TXB2 or had HAPR before surgery and on the 7
th day after OPCAB. A significant 
decrease in serum TXB2 levels on the 2
nd day after OPCAB did not correlate with PLT reactivity. The optimal dose of ASA 
is of interest for further studies of efficacy and clinical outcomes after OPCAB.
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operations such as aortic and/or mitral valve replace-
ment, the preoperative use of a mechanical heart as-
sist device, and an emergency operation. Patients with 
a haematocrit under 25% were also excluded. All opera-
tions were performed without the use of extracorporeal 
circulation.
Blood collection
The effectiveness of acetylsalicylic acid was analysed by 
determining the concentration of thromboxane B2 in blood 
serum as a measure of COX activity in the blood. Labora-
tory evaluation of platelet reactivity was performed using 
the VerifyNow® Aspirin test. Blood samples for analysis 
were collected two hours and 24 hours after taking the 
morning dose of ASA on the day before surgery, and again 
on the second and seventh days after the operation. Blood 
was obtained from an antecubital vein using vacutainer 
tubes containing EDTA for haematological analyses, no 
additive for serum TXB2 measurements and 3.2% sodium 
citrate for whole blood platelet aggregometry (VerifyNow® 
Aspirin test). Complete blood cell counts and mean pla-
telet volume were assessed in samples anticoagulated 
with K3EDTA within 20 minutes of sampling to minimise 
platelet swelling, using a Pentra DX 120 (Horiba Medical, 
Kyoto, Japan).
Anaesthesia and surgical technique
All anaesthetic procedures were performed using the same 
anaesthetic protocol. All surgical procedures were perfor-
med by four surgeons using the same surgical technique. 
After a median sternotomy, the left internal thoracic artery 
was harvested as a bypass conduit. The saphenous vein 
or left radial artery was used to make jump-grafts, Y-grafts 
or T-grafts, as necessary. The conduits were im mersed 
in warm diluted papaverine saline solution (1 mg/mL). 
Systemic heparinisation was achieved with an initial dose of 
1.5 mg/kg heparin, and this was maintained with additional 
heparin doses to reach an activated clotting time above 
300 s. To facilitate anastomosis, the heart was stabilised 
with a suction-type mechanical stabiliser (Octopus; Medtro-
nic, Minneapolis, MN, USA). After the completion of anasto-
mosis, the effect of heparin was reversed with protamine.
Assays for effectiveness of ASA  
and platelet reactivity
Serum TXB2 levels were assessed to measure the inhibition 
of the cyclooxygenase pathway as the primary efficacy 
variable for ASA, as recommended by the European Medi-
cines Agency [9]. Five millilitres of venous blood without 
anticoagulant was sampled in a glass tube, allowed to clot 
at 37°C for 60 min, and centrifuged at 1,200 g for 10 min. 
The serum was stored at −80°C until assayed for TXB2 using 
a commercial enzyme immunoassay (Cayman Chemicals, 
Ann Arbor, MI, USA).
Introduction
Acetylsalicylic acid (ASA) is the most commonly used 
antiplatelet drug in the perioperative period in patients 
undergoing coronary artery bypass grafting (CABG). ASA 
induces platelet dysfunction by irreversible inhibition of 
the cyclooxygenase 1 (COX-1) enzyme in platelets [1]. 
Damage to the vascular endothelium during CABG leads 
to platelet (PLT) activation and many other factors may in-
crease the risk of early thrombotic occlusion of vein grafts. 
Perioperative use of ASA decreases vein graft failure, the 
rate of perioperative cardiovascular complications and, 
consequently, morbidity and mortality [2–4].
The use of cardiopulmonary bypass during CABG inter-
feres with platelet reactivity [5]. Off-pump coronary artery 
bypass grafting (OPCAB) is likely to alter platelet function to 
a lesser extent and may potentially result in high on-aspirin 
platelet reactivity (HAPR) in the postoperative period [6, 7]. 
HAPR is known to be related to graft failure [8]. The effect 
of low-dose acetylsalicylic acid on perioperative platelet 
reactivity in patients who are undergoing OPCAB has rarely 
been studied.
The aim of this study was to characterise serum throm-
boxane B2 (TXB2) variability and ASA-dependent platelet 
reactivity (VerifyNow® Aspirin test) in patients with stable 
coronary artery disease undergoing OPCAB, treated with 
a standard single dose of 75 mg of ASA in the periope-
rative period.
Materials and methods
Patients
In this prospective study, patients with stable coronary 
artery disease scheduled to undergo elective CABG at the 
Department of Cardiac Surgery at the First Department 
of Cardiology of the Medical University of Warsaw were 
screened. All patients were chronically on 75 mg of ASA 
in a single daily dose before the operation. After receiving 
institutional review board approval (KB/154/2012) on 12 
June 2012, and obtaining informed written consent from 
all the patients, we enrolled 25 elective OPCAB patients 
who started the ASA study (EC, enteric-coated tablets; 
Acard®, Warszawskie Zakłady Farmaceutyczne Polfa 
S.A.) regimen one day before surgery and continued until 
the seventh postoperative day. Exclusion criteria were 
unstable angina, acute coronary syndrome or myocar-
dial infarction or percutaneous coronary intervention or 
thrombolysis at least six weeks before the operation, the 
intake of any platelet inhibitor other than enteric-coated 
form of ASA (75 mg) during the four weeks prior to surgery, 
co-medication of non-steroidal anti-inflammatory drugs, 
known bleeding disorder or kidney failure, preoperative 
platelet count outside of the range 100,000–450,000/ 
/μL or a haemoglobin level below 8 g/dL, major combined 
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Assays for platelet function were performed using the 
VerifyNow® Aspirin Assay (Accumetrics Inc., San Diego, 
CA, USA). The VerifyNow® Aspirin Assay is a turbidimetric-
-based optical detection system which measures platelet 
aggregation. It contains a lyophilised preparation of human 
fibrinogen-coated microparticles of arachidonic acid. The 
instrument measures the change of light transmission 
caused by platelet aggregation and reports this value 
in aspirin reaction units (ARU). High on-aspirin platelet 
reactivity was defined as an ARU value ≥ 550 according 
to the manufacturer’s reference values.
Statistics
Statistical analysis was conducted using SPSS 12.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Descriptive stati-
stics were used for all baseline variables, with means and 
standard deviations for normally distributed continuous va-
riables, medians and interquartile ranges for non-normally 
distributed continuous variables, and rates and proportions 
for categorical variables. Categorical data was compared 
with the chi-square test or Fisher’s exact test. Continuo-
us data between the groups was compared by unpaired 
Student’s t-tests for the normally distributed variables 
and the Mann-Whitney rank sum test for the non-normally 
distributed variables. Repeated measurements analysis 
of variance (ANOVA) was used to analyse time-dependent 
data and, if a significant result was obtained, statistical 
comparisons in order to test the within-group change 
between baseline and second day as well as between 
baseline and seventh day were made using the Wilcoxon 
test for correlated means. Contingency tables were used 
for time-dependent change of patient proportions with 
specified variables. Differences were considered significant 
at p values < 0.05.
Results
Patient characteristics
A total of 25 patients with a mean age of 67.9 years (± 10.4 
years) were enrolled consecutively in the study. Baseline 
patient characteristics and perioperative clinical and bio-
chemical results are presented in Table 1 and in Table 2.
Haematological analyses
We observed a significant platelet counts reduction, and 
a mean platelet volumes increase, on the 2nd day after 
OPCAB compared to the preoperative results. A significant 
platelet counts increase without any major change of mean 
platelet volumes was observed on the 7th postoperative 
day (Table 3).
Serum thromboxane B2
Serum TXB2 results are presented in Table 4 and in Figure 1. 
A serum TXB2 decrease on the 2nd day after OPCAB and 
Table 1. Baseline characteristics at recruitment
Patient characteristics Study group 
ASA 1 × 75 
N = 25
Age, [years], mean ± SD 67.99 ± 10.41
Male, N [%] 16 (64)
BMI [kg/m2], mean ± SD 28.63 ± 4.11
CCS 2, N [%] 18 (72)
CCS 3, N [%] 7 (28)
Previous MI, N [%] 12 (48)
Previous PCI, N [%] 5 (20)
LVEF > 50%, N [%] 16 (64)
LVEF 30–50%, N [%] 9 (36)
LVEF < 30%, N [%] 0 (0)
Diabetes mellitus type 2, N [%] 9 (36)
Hypertension, N [%] 22 (88)
Peripheral arterial disease, N [%] 11 (44)
Neurological deficits, N [%] 0 (0)
Chronic obstructive pulmonary  
disease, N [%]
1 (4)
Chronic kidney disease, N [%] 5 (20)
Creatinine > 2.2 mg/dL, N [%] 2 (8)
Hyperlipidaemia, N [%] 9 (36)
EuroSCORE (logistic), mean ± SD 5.55 ± 5.4
Beta-blockers, N [%] 25 (100)
ACEI, N [%] 22 (88)
Calcium channel blockers, N (%) 5 (20)
Statin, N [%] 24 (96)
ASA — acetylsalicylic acid; N — number of patients; SD — standard deviation; [%] — percentage  
of patients; BMI — body mass index; CCS — Canadian Cardiovascular Society Angina Grading Scale; 
MI — myocardial infarction; PCI — percutaneous coronary intervention; LVEF — left ventricular 
ejection fraction; ACEI — angiotensin-converting enzyme inhibitors
an increase on the 7th day after surgery were observed in 
relation to the corresponding preoperative values. A signi-
ficant median serum TXB2 increase was observed between 
measurements at two and 24 hours after taking ASA before 
surgery (p < 0.001).
There was a significant increase (p = 0.01) in the 
percentage of patients with insufficient laboratory ASA 
efficacy (defined by serum TXB2 ≥ 7.2 ng/mL) between the 
measurements obtained at two and 24 hours after ASA 
administration before surgery (20% and 44%, respecti-
vely). There were marked drops in rates of patients with 
serum TXB2 ≥ 7.2 ng/ml (at 24 hours after ASA intake) on 
the 2nd day after OPCAB in relation to preoperative values 
(8% and 44% respectively, p = 0.003). In contrast, the 
percentage of patients with serum TXB2 ≥ 7.2 ng/mL on the 
7th day after OPCAB (at two hours after ASA administration) 
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significantly increased (20% and 52% respectively, p = 
= 0.02) (Table 5, Figure 2).
VerifyNow® Aspirin test
The results of arachidonate-induced platelet reactivity 
from turbidimetric aggregometry in whole blood using the 
VerifyNow® Aspirin test are shown in Table 4 and in Figure 1.
Despite a significant serum TXB2 decrease in the 
whole study population on the 2nd postoperative day, 
platelet reactivity did not change significantly compared 
to preoperative results. A significant increase in median 
platelet reactivity and in the percentage of patients with 
HAPR (defined by VerifyNow® Aspirin test result ≥ 550 ARU) 
were observed on the 7th postoperative day (24 hours after 
taking ASA) in comparison with the values before OPCAB 
(48% and 12% respectively, p = 0.007) (Table 5, Figure 2).
Relationship between platelet counts, mean 
platelet volumes, serum thromboxane B2 
and arachidonic acid-induced platelet 
aggregation
 There was a significant, positive correlation before 
operation between serum TXB2 and platelet reactivity both 
two and 24 hours after ASA intake (rho = 0.4, p = 0.03; rho 
= 0.5, p = 0.01; respectively). On the 2nd postoperative day 
there was a significant, positive correlation between serum 
TXB2 and platelet count two hours after ASA administration 
(rho = 0.5, p = 0.02). On the 7th postoperative day, two 
hours after ASA intake, there was a significant, negative 
correlation between platelet count and mean platelet 
volume (rho = 0.5, p = 0.005) and a significant, positive 
correlation between serum TXB2 and platelet reactivity 
(rho = 0.7, p < 0.001).
The proportion of patients with both serum TXB2 ≥ 7.2 ng/ 
/mL and platelet reactivity ≥ 550 ARU on the 7th post-
operative day was significantly higher (24 hours after ASA 
administration) in relation to preoperative values (32% and 
4% respectively, p = 0.008) (Table 5, Figure 2).
Discussion
We used serum thromboxane as the primary outcome 
measure in our study because it is a sensitive and specific 
measure of the antiplatelet effects of ASA. At least 95% 
suppression of serum TXB2 is required to achieve an opti-
mal antiplatelet effect [10]. In patients chronically treated 
with ASA, a maximum level of serum TXB2 of 10 ng/mL 
corresponds to ≥ 98% inhibition of COX-1 [11]. We used in 
our study an even more rigorous target serum TXB2 con-
centration of ≥ 7.2 ng/mL in accordance with other authors 
[12, 13]. Platelet aggregation studies are also widely used 
to measure the antiplatelet effects of ASA, but are less 
sensitive and specific than serum TXB2. Consistent with 
this, some patients had complete suppression of platelet 
aggregation despite a postoperative rise in serum throm-
boxane level, and vice versa.
Table 2. Perioperative biochemical and clinical characteristics
Biochemical and clinical characteristics Study group 
ASA 1 × 75 
N = 25
Number of anastomoses, mean ± SD 2.68 ± 1.07
Intensive care unit stay [hours], mean 
± SD
56.44 ± 42.01
Mechanical respiratory therapy [hours], 
mean ± SD
8.44 ± 6.25
Troponin I [ng/mL], mean ± SD:
• 6 hours after OPCAB
• 18 hours after OPCAB
• 42 hours after OPCAB
1.88 ± 3.03
3.39 ± 8.62
3.12 ± 8.32
CK-MB mass [ng/mL], mean ± SD:
• 6 hours after OPCAB
• 18 hours after OPCAB
• 42 hours after OPCAB
7.30 ± 8.57
12.03 ± 15.55
8.99 ± 11.66
Chest drainage [mL], mean ± SD:
• 6 hours after OPCAB
• 12 hours after OPCAB
537.4 ± 553.47
754.4 ± 714.4
Haemoglobin [g/dL], mean ± SD:
• day 0
• day 2
• day 7
13.34 ± 1.56
9.95 ± 0.91
10.15 ± 1.07
Table 3. Postoperative platelet (PLT) counts and mean platelet 
volumes (MPV) compared to preoperative levels
Study day PLT [103/µL] 
N = 25
MPV [fL] 
N = 25
Day 0
Min; Max
Median
Q1; Q3
124; 324
195
168; 247
8.3; 12.5
10.4
9.9; 11
Day 2
Min; max
Median
Q1; Q3
53; 239
142
122; 169
8.3; 13.3
11.2
10.5; 12.6
Day 2 vs day 0, p-value < 0.001 0.004
Day 7
Min; max
Median
Q1; Q3
111; 397
256
219; 313
8.2; 12.2
10.4
9.5; 11.3
Day 7 vs day 0, p-value 0.01 0.5
min. — minimum; max. — maximum; Q1 — quartile 1; Q3 — quartile 3; p-value — probability value
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We observed a decline in platelet counts following 
OPCAB surgery on day 2 and this was followed by a rise 
in platelet counts to levels higher than baseline. Although 
almost all patients had nearly complete suppression of 
serum TXB2 on the second postoperative day, there was 
a subsequent rise in serum TXB2 levels that occurred in 
parallel with the postoperative increase in platelet counts.
The drop in haemoglobin levels and platelet counts 
with mean platelet volume increase on the 2nd day after 
OPCAB reflects blood loss and haemodilution during the 
Table 4. Serum thromboxane B2 (TXB2) levels and arachidonate-
-induced platelet aggregation results in whole blood measured  
by VerifyNow® Aspirin Assay
Study day TXB2 [g/mL] 
N = 25
VerifyNow® 
Aspirin (ARU) 
N = 25
Day 0, 2 h
Min; max
Median
Q1; Q3
0.16; 74.37
3.25
1.33; 6.68
384; 645
514
424; 534
Day 0, 24 h
Min; max
Median
Q1; Q3
0.32; 83.01
6.14
3.53; 9.88
383; 650
445
424; 477
Day 0, 24 h vs 2 h, p-value < 0.001 0.06
Day 2, 2 h
Min; max
Median
Q1; Q3
0.09; 10.8
0,4
0.23; 0.98
378; 605
517
484; 544
Day 2, 24 h
Min; max
Median
Q1: Q3
0.05; 13.01
0.5
0.29; 0.66
377; 583
495
423; 513
Day 2, 24 h vs 2 h, p-value 0.3 0.02
Day 2 vs day 0, 2 h, p-value < 0.001 0.2
Day 2 vs day 0, 24 h, p-value < 0.001 0.2
Day 7, 2 h
Min; max
Median
Q1; Q3
0.25; 55.35
8.57
1.91; 18.08
367; 643
540
453; 594
Day 7, 24 h
Min; max
Median
Q1; Q3
0.51; 64
13.09
3.18; 24.74
403; 644
544
465; 604
Day 7, 24 h vs 2 h, p-value 0.8 0.6
Day 7 vs day 0, 2 h, p-value 0.04 0.1
Day 7 vs day 0, 24 h, p-value 0.06 0.003
Figure 1. Serum thromboxane B2 (TXB2) levels (A) and arachido-
nate-induced platelet reactivity results measured by VerifyNow® 
Aspirin test (B). Box and whisker plots of daily perioperative serum 
TXB2 levels in the treatment group (ASA 1 × 75 — acetylsalicylic 
acid [ASA] 75 mg once-daily). The horizontal line contained within 
the box represents the median, the upper and lower ends of the 
box represent the 25th and 75th centiles, the upper and lower hori-
zontal lines at the end of the whiskers represent the maximum and 
minimum levels and the small open circles outside the whiskers 
represent outliers; 0d2h — day 0 before surgery, 2 hours after ASA 
intake; 2d24 — day 2, 24 hours after ASA intake etc.
early postoperative period. A significant increase in platelet 
counts on the 7th postoperative day may be associated 
with high platelet turnover and can result in reduced an-
tiplatelet activity of ASA [14]. Enhanced platelet turnover, 
which corresponds with platelet hyperactivity, causes the 
release of young platelets still able to form thromboxane 
via uninhibited COX-1 and possibly through up-regulated 
COX-2 generating critical amounts of thromboxane despite 
antiplatelet treatment.
The important finding of our study is that nearly half 
of all the patients taking 75 mg of enteric-coated ASA 
preparations daily failed to attain optimal inhibition of 
serum TXB2 or had HAPR on the 7
th day after OPCAB. 
Reasons for the failure to respond to ASA may be phar-
macokinetic (failure to achieve an adequate level of drug) 
A
B
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or pharmacodynamic (failure to inhibit platelet function). 
Poor patient compliance, interindividual pharmacodynamic 
variability, inadequate dosing, and drug interaction must 
also be considered. We went to considerable lengths to 
ensure patient compliance (every ASA intake was made 
in the presence of hospital staff) and prevent drug intera-
ction (every ASA ingestion was made three hours before 
any other drug intake). The administration of NSAIDs can 
prevent COX acetylation by ASA, and we did not use NSAIDs 
in the postoperative period [15].
These days, many patients who take ASA as antiplatelet 
therapy for the secondary prevention of cardiovascular 
events receive low-dose EC preparations. Dose-finding 
studies, on which current regimens are based, used plain 
ASA which differs significantly in its pharmacokinetic profile 
from EC preparations. With plain ASA preparations, peak 
plasma levels occur 30 to 40 minutes after ingestion and 
platelet inhibition is apparent after one hour. It takes 
3–4 hours to achieve peak plasma levels with EC ASA [16]. 
Bioavailability of EC ASA may be lower than plain ASA due 
to slower absorption and a more alkaline environment in 
the upper small intestine. If immediately before ingestion 
of the daily ASA dose a significant amount of circulating 
platelets are competent for thromboxane formation, cir-
cadian inhibition of platelet function may be incomplete. 
Reduced suppression of thromboxane has been linked 
with an increased risk of premature graft failure following 
CABG surgery [17].
Even though most studies have shown the potential of 
platelet function testing to predict atherothrombotic events 
after CABG, the evidence is still insufficient to recommend 
routine platelet function testing to guide treatment in CABG 
patients for this purpose [18–20]. The results of our study 
suggest that the dose of ASA delivered by 75 mg of EC 
tablets is insufficient to prevent platelet activity in many 
patients after OPCAB.
Table 5. Rates of patients stratified by results of serum thromboxane B2 (TXB2) ≥ 7.2 ng/mL, arachidonate-induced platelet reactivity  
≥ 550 ARU and both serum TXB2 ≥ 7.2 ng/mL and arachidonate-induced platelet reactivity ≥ 550 ARU
Study day Patients, N [%], 
stratified by TXB2 
< 7.2 ng/mL 
vs ≥ 7.2 ng/mL
Patients, N (%), 
stratified by VerifyNow® 
Aspirin 
< 550 ARU 
vs ≥ 550 ARU
Patients, N (%), 
stratified by TXB2 < 7.2 ng/mL 
and VN < 550 ARU 
vs ≠ (TXB2 ≥ 7.2 ng/mL  
and VN ≥ 550 ARU)
Day 0, 2 h 20 (80%) 
vs 
5 (20%)
20 (80%) 
vs 
5 (20%)
24 (96%) 
vs 
1 (4%)
Day 0, 24 h 14 (56%) 
vs 
11 (44%)
22 (88%) 
vs 
3 (12%)
22 (88%) 
vs 
3 (12%)
Day 0, 24 h vs 2 h, p-value 0.01 0.4 0.2
Day 2, 2 h 23 (92%) 
vs 
2 (8%)
19 (76%) 
vs 
6 (24%)
23 (92%) 
vs 
2 (8%)
Day 2, 24 h 23 (92%) 
vs 
2 (8%)
22 (88%) 
vs 
3 (12%)
24 (96%) 
vs 
1 (4%)
Day 2, 24 h vs 2 h, p-value 1.0 0.3 0.3
Day 2 vs day 0, 2 h, p-value 0.08 0.7 0.3
Day 2 vs day 0, 24 h, p-value 0.003 1.0 0.3
Day 7, 2 h 12 (48%) 
vs 
13 (52%)
14 (56%) 
vs 
11 (44%)
17 (68%) 
vs 
8 (32%)
Day 7, 24 h 9 (36%) 
vs 
16 (64%)
13 (52%) 
vs 
12 (48%)
17 (68%) 
vs 
8 (32%)
Day 7, 24 h vs 2 h, p-value 0.2 0.7 1.0
Day 7 vs day 0, 2h, p-value 0.02 0.1 0.008
Day 7 vs day 0, 24 h, p-value 0.2 0.007 0.1
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Limitations of the study
Our study was underpowered for clinical events, but our results 
nonetheless provide clear-cut clues to more efficient periope-
rative ASA dosages than 75 mg enteric-coated formulation.
Conclusions
In the group of patients taking a standard daily dose of 
75 mg of ASA, a substantial number of patients failed to 
attain optimal inhibition of serum TXB2 or had HAPR be-
fore surgery and on the 7th day after OPCAB. A significant 
decrease in serum TXB2 levels on the 2
nd day after OPCAB 
did not correlate with platelet reactivity. The optimal dose of 
Figure 2. Analysis of patients % stratified by levels of serum thromboxane B2 (TXB2) ≥ 7,2 ng/mL or/and results of VerifyNow® Aspirin 
≥ 550 ARU
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Streszczenie
Wstęp. Kwas acetylosalicylowy (ASA) jest podstawowym lekiem przeciwpłytkowym stosowanym w okresie okołoopera-
cyjnym u chorych poddawanych operacjom pomostowania tętnic wieńcowych (CABG). Operacja pomostowania tętnic 
wieńcowych bez użycia krążenia pozaustrojowego (OPCAB) prawdopodobnie w mniejszym stopniu zaburza funkcję pły-
tek krwi (PLT) niż operacja wykonywana w krążeniu pozaustrojowym i może być przyczyną wysokiej reaktywności płytek 
mimo leczenia ASA (HAPR) w okresie pooperacyjnym.
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Materiały i metody. Celem badania była prospektywna analiza zmienności stężenia tromboksanu B2 (TXB2) w surowicy 
krwi i reaktywności PLT zależnej od ASA u pacjentów ze stabilną chorobą wieńcową, poddanych OPCAB, leczonych stan-
dardową, pojedynczą dawką dobową 75 mg ASA. Próbki krwi do analizy pobierano po 2 i 24 h od przyjęcia porannej 
dawki ASA w dobie poprzedzającej operację, a następnie w 2. i 7. dobie po operacji.
Wyniki. W 2. dobie po OPCAB obserwowano istotne zmniejszenie liczby PLT oraz zwiększenie średniej objętości płytek 
krwi. W 7. dobie pooperacyjnej stwierdzono zwiększenie liczby PLT wobec wartości przed operacją. W 7. dobie po OP-
CAB obserwowano istotne zwiększenie w odniesieniu do wartości przed operacją odsetka pacjentów z niedostateczną 
w analizie laboratoryjnej skutecznością leczenia przeciwpłytkowego ASA (definiowaną jako stężenie TXB2 w surowicy krwi 
≥ 7,2 ng/ml), odpowiednio 52% w porównaniu z 20%; p = 0,02. W 7. dobie pooperacyjnej stwierdzono znamienny wzrost 
mediany reaktywności PLT oraz odsetka pacjentów z HAPR (wynik testu VerifyNow® Aspirin ≥ 550 ARU) w porównaniu 
z wartościami przed OPCAB (odpowiednio 48% v. 12%; p = 0,007).
Wnioski. W grupie pacjentów stosujących pojedynczą, dobową dawkę 75 mg ASA u istotnego odsetka badanych 
(p = 0,03) przed operacją oraz w 7. dobie po OPCAB stwierdzono suboptymalne zahamowanie syntazy TXB2 oraz HAPR. 
Znamienne obniżenie stężenia TXB2 w surowicy krwi w 2. dobie pooperacyjnej nie korelowało z reaktywnością PLT. 
W przyszłych badaniach dotyczących efektywności leczenia przeciwpłytkowego oraz wyników klinicznych po OPCAB 
należy zwrócić szczególną uwagę na optymalizację dawkowania ASA.
Słowa kluczowe: kwas acetylosalicylowy, pomostowanie tętnic wieńcowych, tromboksan, reaktywność płytek krwi
Folia Cardiologica 2018; 13, 5: 407–415
8. Une D, Kulik A, Voisine P, et al. Correlates of saphenous vein graft 
hyperplasia and occlusion 1 year after coronary artery bypass 
grafting: analysis from the CASCADE randomized trial. Circulation. 
2013; 128(11, Suppl 1): 213–218, doi: 10.1161/CIRCULATION-
AHA.112.000328, indexed in Pubmed: 24030409.
9. The European Agency for the Evaluation of Medicinal Products. Posi-
tion paper on the regulatory requirements for the authorisation of low-
-dose modified release asa formulations in the secondary prevention 
of cardiovascular events. Evaluation of Medicines for Human Use. 
2002: 1–4.
10. McAdam B, Keimowitz RM, Maher M, et al. Transdermal modification 
of platelet function: an aspirin patch system results in marked sup-
pression of platelet cyclooxygenase. J Pharmacol Exp Ther. 1996; 
277(2): 559–564, indexed in Pubmed: 8627531.
11. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic intera-
ction of naproxen with low-dose aspirin in healthy subjects. J Am Coll 
Cardiol. 2005; 45(8): 1295–1301, doi: 10.1016/j.jacc.2005.01.045, 
indexed in Pubmed: 15837265.
12. Patrono C, Rocca B. Drug insight: aspirin resistance — fact or fashion? 
Nat Clin Pract Cardiovasc Med. 2007; 4(1): 42–50, doi: 10.1038/ 
/ncpcardio0728, indexed in Pubmed: 17180149.
13. Mortensen SB, Larsen SB, Grove EL, et al. Reduced platelet response 
to aspirin in patients with coronary artery disease and type 2 diabe-
tes mellitus. Thromb Res. 2010; 126(4): 318–322, doi: 10.1016/j.
thromres.2010.03.013, indexed in Pubmed: 20451957.
14. Arazi HC, Doiny DG, Torcivia RS, et al. Impaired anti-platelet effect of 
aspirin, inflammation and platelet turnover in cardiac surgery. Inte-
ract Cardiovasc Thorac Surg. 2010; 10(6): 863–867, doi: 10.1510/ 
/icvts.2009.229542, indexed in Pubmed: 20233808.
15. Catella-Lawson F, Reilly M, Kapoor S, et al. Cyclooxygenase inhibitors 
and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 
1809–1817, doi: 10.1056/nejmoa003199.
References
1. Vane JR, Botting RM, Moncada S, et al. Inhibition of prostaglandin 
synthesis as a mechanism of action for aspirin-like drugs. Nat New 
Biol. 1971; 231(25): 232–235, indexed in Pubmed: 5284360.
2. Windecker S, Kolh P, Alfonso F, et al. The Task Force on Myocardial 
Revascularization of the European Society of Cardiology (ESC), Eu-
ropean Association for Cardio-Thoracic Surgery (EACTS), European 
Association of Percutaneous Cardiovascular Interventions (EAPCI). 
2014 ESC/EACTS guidelines on myocardial revascularization. Eur 
Heart J. 2014; 35(37): 2541–2619, doi: 10.1093/eurheartj/ehu278, 
indexed in Pubmed: 25173339.
3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis 
of randomised trials of antiplatelet therapy for prevention of death, 
myocardial infarction, and stroke in high risk patients. BMJ. 2002; 
324(7329): 71–86, indexed in Pubmed: 11786451.
4. Sousa-Uva M, Storey R, Huber K, et al. ESC Working Group on Cardio-
vascular Surgery, ESC Working Group on Thrombosis. Expert position 
paper on the management of antiplatelet therapy in patients under-
going coronary artery bypass graft surgery. Eur Heart J. 2014; 35(23): 
1510–1514, doi: 10.1093/eurheartj/ehu158, indexed in Pubmed: 
24748565.
5. Li N, Astudillo R, Ivert T, et al. Biphasic pro-thrombotic and inflammato-
ry responses after coronary artery bypass surgery. J Thromb Haemost. 
2003; 1(3): 470–476, indexed in Pubmed: 12871452.
6. Khan NE, De Souza A, Mister R, et al. A randomized comparison of 
off-pump and on-pump multivessel coronary-artery bypass surgery. 
N Engl J Med. 2004; 350(1): 21–28, doi: 10.1056/NEJMoa031282, 
indexed in Pubmed: 14702424.
7. Widimsky P, Straka Z, Stros P, et al. One-year coronary bypass graft pa-
tency: a randomized comparison between off-pump and on-pump sur-
gery — angiographic results of the PRAGUE-4 trial. Circulation. 2004; 
110(22): 3418–3423, doi: 10.1161/01.CIR.0000148139.79580.36, 
indexed in Pubmed: 15557371.
415www.journals.viamedica.pl/folia_cardiologica
Radosław Wilimski et al., Effect of low-dose ASA on platelet reactivity after OPCAB
16. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the re-
lationships among dose, effectiveness, and side effects: the Seventh 
ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 
2004; 126(3): 234–264, doi: 10.1378/chest.126.3_suppl.234S, in-
dexed in Pubmed: 9822058.
17. Gluckman TJ, McLean RC, Schulman SP, et al. Effects of aspirin 
responsiveness and platelet reactivity on early vein graft thrombosis 
after coronary artery bypass graft surgery. J Am Coll Cardiol. 2011; 
57(9): 1069–1077, doi: 10.1016/j.jacc.2010.08.650, indexed in 
Pubmed: 21349398.
18. Rafiq S, Johansson PI, Zacho M, et al. Thrombelastographic haemo-
static status and antiplatelet therapy after coronary artery bypass 
surgery (TEG-CABG trial): assessing and monitoring the antithrom-
botic effect of clopidogrel and aspirin versus aspirin alone in hy-
percoagulable patients: study protocol for a randomized controlled 
trial. Trials. 2012; 13: 48, doi: 10.1186/1745-6215-13-48, indexed 
in Pubmed: 22540524.
19. Kim HJ, Lee JM, Seo JH, et al. Preoperative aspirin resistance does 
not increase myocardial injury during off-pump coronary artery bypass 
surgery. J Korean Med Sci. 2011; 26(8): 1041–1046, doi: 10.3346/ 
/jkms.2011.26.8.1041, indexed in Pubmed: 21860554.
20. Janssen PWA, ten Berg JM, Hackeng CM. The use of platelet function 
testing in PCI and CABG patients. Blood Rev. 2014; 28(3): 109–121, 
doi: 10.1016/j.blre.2014.03.004, indexed in Pubmed: 24745727.
